Nov 29, 2022 / NTS GMT
Carlos de Sousa - Ultimovacs ASA - CEO
Good afternoon, everybody. It's a pleasure to be here. My name is Carlos de Sousa. I'm the CEO of Ultimovacs. Ultimovacs is a publicly listed company in the Euronext Oslo Stock Exchange. And that's why I need to show you the slide. And we are located in Oslo, and we also have a team in Uppsala.
So what does Ultimovacs do? Ultimovacs is operating in the field of immuno-oncology with a next-generation universal cancer vaccine, with several benefits among them the fact that it is easy to administer, just as intradermal injections. It's also a truly off-the-shelf product, ready to be administered when needed. And we basically stimulate, educate the immune system to recognize cancer cells. And we are using combination with checkpoint inhibitors.
We improve the efficacy of checkpoint inhibitors. As you know, checkpoint inhibitors don't kill cancer cells. They just block their defenses, so you need an active immune system to penetrate the tumor and kill the cancer cells. And that's what we do. We basically, our goal is to be used as a backbone across multiple
Ultimovacs ASA at Biostock Life Science Fall Summit Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot